Henrik Grönberg

Henrik Grönberg

Professor/Överläkare
E-postadress: henrik.gronberg@ki.se
Telefon: +46852482347
Besöksadress: Nobels väg 12a, 17165 Solna
Postadress: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Grönberg, 171 77 Stockholm
Del av:

Om mig

  • Jag är professor i cancerepidemiologi vid Karolinska Institutet och chef för Prostatacancercentrum, Capio S:t Görans sjukhus, Stockholm. Mitt huvudsakliga forskningsområde är prostatacancergenetik med fokus på att identifiera nya markörer både för risken att få prostatacancer och för prognosen för prostatacancer efter diagnos.

    Jag har utvecklat STHLM3 - ett blodprov som kombinerar proteinmarkörer, genetiska markörer och kliniska data med en avancerad algoritm för att upptäcka aggressiv prostatacancer i ett tidigt skede och är PI för ProBio-studien som syftar till att identifiera biomarkörer som förutsäger behandlingssvar bland män med metastaserad prostatacancer.

    Mellan 2008 och 2013 var jag prefekt vid institutionen för medicinsk epidemiologi och biostatistik vid Karolinska Institutet och 2016 tjänstgjorde jag som tillförordnad prorektor vid Karolinska Institutet.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Cancerfonden
    1 January 2025 - 31 December 2027
  • Cancerfonden
    1 January 2024 - 31 December 2026
  • Cancerfonden
    1 January 2022 - 31 December 2024
  • Swedish Research Council
    1 January 2022 - 31 December 2025
    The lack of treatment-predictive biomarkers is an unmet clinical need in metastatic prostate cancer leading to inferior clinical outcomes, overtreatment and accelerating costs. The ProBio study (NCT03903835) is an ongoing randomized trial that builds on a novel adaptive study design and prospectively evaluates treatment predictive biomarker signatures in a large network of over 35 study centers in Europe. By using ProBio we will be able to rapidly evaluate both new and old drugs in subsets of patients with similar genomic biomarker. If successful, patients with prostate cancer will get individualized treatment based on treatment-predictive genomic biomarker signatures in the near future.To test this hypothesis, we will use a multiphase randomized study using an outcome-adaptive multi-arm biomarker-driven study design. We have the following main aims: To investigate if treatment decisions based on a biomarker signature identified by sequencing circulating tumor DNA improves progression free survival (primary endpoint)To ultimately show that the ProBio concept is a model for collaboration between academia and industry in the evaluation of new drugs in prostate cancer
  • Swedish Research Council
    1 January 2021 - 31 December 2024
  • Swedish Research Council
    1 January 2020 - 31 December 2020
  • Swedish Research Council
    1 January 2020 - 31 December 2023
  • VINNOVA
    15 March 2019 - 31 December 2021
  • Nordic implementation of personalised prostate cancer diagnostics
    NordForsk
    1 January 2019 - 31 December 2020
  • Swedish Research Council
    1 January 2019 - 31 December 2021
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Tomorrow's Prostate Diagnostics - A Highly Improved Diagnosis That Leads to Reduced Over and Under Diagnosis and Improved Survival in Sweden's Most Common Cancer
    Swedish Cancer Society
    1 January 2018
    Prostate cancer is Sweden's most common cancer. Each year, over 10,000 men suffer from prostate cancer and 2,300 die from their disease. Unfortunately, today's diagnostics are substandard. This means that many men are over-treated while many aggressive and demanding prostate cancers are never treated. In recent years, our and others' research has shown that prostate cancer diagnosis can be improved by using the Stockholm3 test instead of PSA, improving the tissue sampling with magnetic camera followed by targeted biopsies and by genomically analyzing the tumor to choose the right treatment. My research group has identified the three key areas in prostate cancer diagnostics where we believe that improvements provide the most value for future patients. First, we will validate the Stockholm3 test in various healthcare systems within the EU. On the one hand, we carry out a randomized clinical study that can provide a basis for the National Board of Health and Welfare to introduce screening for prostate cancer. Finally, we will carry out a large randomized study that provides molecular support for the choice of treatment if one is to suffer from spread prostate cancer. All studies will be carried out at high speed to bring value to patients of the future as soon as possible. If we succeed with our academically driven studies, these will have a great impact on healthcare. For the patient, this means that in the near future we will be able to greatly reduce over- and under-diagnosis while at the same time increasing the survival of prostate cancer. For society, this will mean lower costs for diagnosis and care of prostate cancer and that critical resources in urology, pathology and oncology are used in a better way and more fairly.
  • Swedish Research Council
    1 January 2018 - 31 December 2020
  • Swedish Research Council
    1 December 2017 - 31 December 2020
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 January 2017
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test • Evaluate how to combine the STHLM3 test with MRI (MRI) • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 January 2016
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test   • Evaluate how to combine the STHLM3 test with MRI (MRI)   • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Swedish Research Council
    1 January 2016 - 31 December 2018
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2016 - 31 December 2018
  • Clinical implementation of genetic markers in prostate cancer
    Swedish Cancer Society
    1 January 2015
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. One way to reduce mortality is to diagnose prostate cancer as early as possible. Today, the PSA test is used, but we have now developed a better combined test STHLM3 test that is clearly better than PSA. We work on developing the diagnosis of prostate cancer and in the best way find the prostate cancers that are dangerous and need treatment. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies we try to develop various tests that enable us to find and treat the more dangerous cancers as early as possible. With this research program we want:   • Further develop the STHLM3 test • Evaluate how to combine the STHLM3 test with MRI (MRI) • Develop a tumor test that can determine whether a man needs treatment or not for his prostate cancer
  • Genetic factors in prostate cancer: from genes to clinic
    Swedish Cancer Society
    1 January 2014
    Prostate cancer is the most common cancer in men in Sweden today and over 10,000 men are diagnosed annually. Over 2,500 men die from prostate cancer, making it the most common cancer-related cause of death in Sweden. Prostate cancer is caused by a combination of hereditary factors and lifestyle factors. Most epidemiological studies have shown that men with close relatives with prostate cancer have 2 to 3 times greater risk of getting into the same cancer. Twin studies have also shown that over 40% of the risk factors are inherited in prostate cancer. In recent years, at least 70 genetic variants have been identified that increase the risk of prostate cancer. We have collected blood samples and tumor material in 3 different large studies from about 10,000 men with prostate cancer and 25,000 healthy men. From these studies, we analyze different genetic markers to see if they are associated with the risk of getting prostate cancer. We use several different statistical and molecular genetic methods. Our research deals with a disease that is of great importance since over 2,500 men die in prostate cancer in Sweden annually. With our studies, we try to identify genetic variations or tumor markers that are important both for the origin and development of prostate cancer. With this research program we want: - Developing genetic tests for prostate cancer diagnosis
    - Identify tumor markers for aggressive prostate cancer
    - Drive clinical trials evaluating the benefits of new genetic tests for prostate cancer.
  • Visa fler

Anställningar

  • Professor/Överläkare, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2020-

Nyheter från KI

Kalenderhändelser från KI